- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Medical Bulletin 21/December/2021 - Video
Overview
Here are Top Medical stories of the day
Calcitriol, Sirolimus combo helps treat ITP
Overall efficacy of calcitriol combined with sirolimus in the treatment of chronic primary immune thrombocytopenia (cITP) in adults is satisfactory, according to a recent study published in the Zhongguo Shi Yan Xue Ye Xue Za Zhi.
A study was conducted to investigate the clinical efficacy of calcitriol combined with sirolimus in the treatment of chronic primary immune thrombocytopenia (cITP) patients.
For more details, check out the full story on the link below:
Calcitriol And Sirolimus Combo Effective In Treating Chronic Primary Immune Thrombocytopenia: Study
Cataract surgery is challenging in short eyes, with increased complication rates and poorer postoperative refractive predictability. Short eyes include simple microphthalmos, complex microphthalmos, nanophthalmos and relative anterior microphthalmos.
Simple or isolated microphthalmos is an eye shorter than the mean by two standard deviations (typically<21.0 mm) with a normal anterior chamber depth and scleral thickness and no anatomical malformations.
For more details, check out the full story on the link below:
Cataract Surgery In Short Eyes: Visual Outcomes, Complications And Refractive Results
Acrokeratosis verruciformis of Hopf: dermoscopic and histopathological study- Acrokeratosis verruciformis of Hopf (AVH) is an autosomal dominant genodermatosis. It is caused by a mutation in the ATP2A2 gene, located on chromosome 12q24. Both AVH and Darier disease are believed to be allelic disorders. Familial cases of AVH usually have early onset either at birth or childhood, while sporadic cases usually present later in life. Recently dermoscopy of AVH has been described in Clinical and Experimental Dermatology journal.
Two siblings, a 7-year-old boy and a 5-year-old girl born to nonconsanguineous parents presented with a 4-year history of multiple, asymptomatic, skin-coloured papules. The lesions were present mainly over the dorsal aspects of the forearms in the boy and ventral aspect of the forearm and the antecubital fossa in the girl.
For more details, check out the full story on the link below:
Dermoscopy Can Help Diagnose AVH, Obviating Need For Biopsy: Study
Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission. A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions of the disease.
The findings, to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, update the early results of this study that were published in 2019 study of the regimen in 85 patients with previously untreated CLL. Nearly all the patients were in remission at the 16.5-month mark; the updated data confirm those benefits to be continuing now at a median of 40.3 months.
For more details, check out the full story on the link below:
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)